| Project/Area Number |
16K20154
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
Iida Keitaro 名古屋市立大学, 大学院医学研究科, 臨床研究医 (30713945)
|
|---|
| Research Collaborator |
Yasui Takahiro 名古屋市立大学, 大学院医学研究科, 教授 (40326153)
Suzuki Takayoshi 京都府立医科大学, 大学院医学研究科, 教授 (90372838)
Kawai Noriyasu 名古屋市立大学, 大学院医学研究科, 准教授 (20254279)
Ando Ryosuke 名古屋市立大学, 大学院医学研究科, 講師 (30381867)
Naiki Taku 名古屋市立大学, 大学院医学研究科, 助教 (50551272)
Etani Toshiki 名古屋市立大学, 大学院医学研究科, 助教 (30600754)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | エピジェネティクス / ヒストン修飾 / LSD1 / 膀胱癌 / オートファジー / エピゲノム / アポトーシス / 膀胱癌臨床検体 / ヒストン脱メチル化 / 薬剤耐性 / NCL1 |
|---|
| Outline of Final Research Achievements |
We investigated therapeutic potential of a novel histone lysine demethylase 1 (LSD1) inhibitor, NCL1, in bladder cancer. Bladder cancer cell lines were treated with NCL1, and LSD1 and cell viability were assessed. Bladder cancer cells showed strong LSD1 expression, and cell viability was decreased by NCL1. In addition, autophagy was induced by NCL1 treatment. Autophagy inhibitor, chloroquine, demonstrated synergic anti-tumor effect with NCL1. In TCGA database, LSD1 RNA expression in bladder cancer was significant higher than that in normal bladder tissues. We suggest that NCL1 and autophagy inhibitor is a potential therapeutic agent for bladder cancer.
|
